Serum metabolites with diagnostic potential in prostate cancer and the inhibitory effects of alpha-Tocomonoenol on prostate cancer cells

Ninghan Feng^1,2*Yang Shen²Bo Liu³Yuhua Zhou⁴Jing Lv⁴Xiang Zhang³Chun Yang^2*Yuwei Zhang^3*

• ¹Wuxi No.2 People's Hospital, Nanjing Medical University, Wuxi, China
• ²Nanjing Medical University, Nanjing, China
• ³Nantong University School of Medicine, Nantong, China
• ⁴Jiangnan University Wuxi School of Medicine, Wuxi, China

Prostate cancer, the most common male urinary system malignant disease, is seriously endangering men's health. At present, prostate cancer early detection is mainly based on prostate-specific antigen screening. However, prostate-specific antigen has the characteristics of high sensitivity but low specificity. Patients with the prostate-specific antigen gray zone level of 4-10ng/ml may be subject to excessive medical interventions. Therefore, the search for new diagnostic indicators for prostate cancer is still of great significance. We enrolled in a total of 60 subjects in this study, comprising 30 prostate cancer patients and 30 benign prostatic hyperplasia patients. Non-targeted metabolomics analysis was performed in the present study. The profiling results were statistically analyzed, and a diagnostic model was constructed using stepwise regression. Six differential metabolites between the two groups were used to construct a diagnostic model (AUC=0.9433). Experimental verification was carried out on the alpha-Tocomonoenol, which was one of the key metabolites. Meanwhile, we found that adding alpha-Tocomonoenol to LNCaP and 22Rv1 would inhibit cells proliferation by binding to androgen receptors. And there was no significant effect on the proliferation of RWPE-1. Finally, we believe that Serum metabolites possess the potential to function as the diagnostic biomarker for the early detection of prostate cancer. And alpha-Tocomonoenol might inhibit the proliferation of prostate cancer cells by binding to androgen receptors.